Last reviewed · How we verify
Standard Arm - Fulvestrant
At a glance
| Generic name | Standard Arm - Fulvestrant |
|---|---|
| Also known as | Fulvestrant |
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- SNV4818 in Participants With Advanced Solid Tumors (PHASE1, PHASE2)
- Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors (PHASE1, PHASE2)
- Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PHASE3)
- Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors (PHASE1, PHASE2)
- Metastasis-directed Therapy for Oligometastases of Breast Cancer (PHASE3)
- Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) (PHASE3)
- Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer (PHASE2)
- Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |